Hypersplenism
7
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection
Transfemoral Versus Transradial Partial Splenic Artery Embolization in Patients With Hypersplenism
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension
Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension
Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)